Finoriq research workspace
Biomea Fusion, Inc. (BMEA) SEC Filings & Filing Highlights
Review SEC filings, SEC-derived company events, filing highlights, source excerpts, and material disclosure activity for Biomea Fusion, Inc. (BMEA).
Company Snapshot
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
- Company
- Biomea Fusion, Inc. (BMEA)
- Ticker
- BMEA
- Market Cap
- $94M
- Latest Price
- $1.30
- Industry
- Biotech & Pharma
Biomea Fusion, Inc. (BMEA) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Biomea Fusion, Inc. (BMEA).
| Event | Form | Date |
|---|---|---|
| The proposals set forth below were submitted to the stockholders at the Annual Meeting of Stock...The proposals set forth below were submitted to the stockholders at the Annual Meeting of Stockholders (the “Annual Meeting”) held on June... | 8-K5.07 | 2026-06-11 |
| Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate HighlightsBiomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights | 8-K2.02 | 2026-05-11 |
| COVALENT-112 Topline Results BIOMEA FUSION CONFERENCE CALL 28 APRIL 2026 Icovamenib in Type 1 D...COVALENT-112 Topline Results BIOMEA FUSION CONFERENCE CALL 28 APRIL 2026 Icovamenib in Type 1 Diabetes Exhibit 99.1 | 8-K8.01 | 2026-04-28 |
| COVALENT-112 Topline Results BIOMEA FUSION CONFERENCE CALL 28 APRIL 2026 Icovamenib in Type 1 D...COVALENT-112 Topline Results BIOMEA FUSION CONFERENCE CALL 28 APRIL 2026 Icovamenib in Type 1 Diabetes Exhibit 99.1 | 8-K7.01 | 2026-04-28 |
| Biomea Fusion Reports Full Year 2025 Financial Results and Corporate HighlightsBiomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights | 8-K2.02 | 2026-03-24 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.